The Navy Put a Startup’s Hypersonic Missile Into Production. Its Investors Paid for the Development First.

On September 14 Castelion announced a Navy delivery order worth up to $200 million to manufacture, test and deliver a first production lot of Blackbeard, a hypersonic strike missile for carrier fighters. The Navy had selected Blackbeard in February, seven months earlier. In 2024 it had cancelled HALO, its own program for an air-launched hypersonic anti-ship missile, citing budget constraints. The Navy's release calls the Blackbeard award one of the first successes of its rapid capabilities office. Castelion says it developed the missile with hundreds of millions of dollars of private investment, and that money is what let the Navy move this fast.

What the investors paid for

The award is a Phase III order under the Small Business Innovation Research program, the phase meant for turning earlier work into products the government buys. The Navy's release says the order uses a provision in the 2026 defense authorization act written for technology developed with private capital. That route lets the Navy move it straight into production. The release says it avoids millions of dollars in redundant non-recurring engineering, the one-time cost of designing and qualifying a product before the first unit ships. A government development program such as HALO carries that engineering on its own budget.

Before this order the Navy made three smaller awards: nearly $50 million in February, when it selected Blackbeard for a program called the Multi-mission Affordable Capacity Effector; $23.4 million in June for 50 pre-production rounds and their shipping containers; and about $90 million in August to bring the missile to early operational capability. They are separate from the $200 million production order, and each was sized for a buyer checking a design that already existed.

The unit cost came first

Castelion's other advantage is a price it set before the buyer asked. USNI News reports that the company aims to keep Blackbeard near half a million dollars a round. The Pentagon said in July it was interested in up to 12,000 of them over five years. At half a million dollars each, that is about $6 billion. Castelion's CEO, Bryon Hargis, says the missile was engineered for the production line from its first day.

Hospitals have enforced the same unit-cost discipline since COVID. Their capital committees stopped paying for equipment whose economics might work later, so a surgical robot's price has to make sense at its very first hospital.

The stage your buyer pays for

Defense has a stage where the buyer pays for work that might fail: development and qualification. A hospital has one too, often a clinical evaluation its own staff run before it buys. Its pace follows the buyer's budget cycle. Castelion paid for the Navy's version of that stage with private money, so by the time the Navy looked, the risky engineering was done and what remained was a purchase.

Castelion's investors held the technical risk for that stage before any order existed. The company's revenue also rests on how much the military actually buys. The Pentagon described its 12,000 as an interest. The Navy's fiscal 2027 budget request funds 353 missiles under the MACE program, for $156 million. A founder weighing the same move should model the year where the customer buys the first lot and then waits.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →